Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LQDA with free AI briefings, catalyst countdowns, and dilution alerts.

LQDA · Liquidia Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$396.1M Cash on Hand
CF+ Cash Runway
Follow LQDA by email Get an email when LQDA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LQDA, unsubscribe in one click. Privacy

📣 What LQDA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
L606 Pulmonary Hypertension Due to Lung Disease (Disorder) Phase 3 · NCT07285655 Recruiting
LIQ861 Inhaled Treprostinil Primary Pulmonary Hypertension Phase 3 · NCT03992755 Active not recruiting
Trivalent Influenza Vaccine Influenza Phase 1/2 · NCT01224262 Completed
Inhaled dry powder treprostinil (LIQ861) Pulmonary Arterial Hypertension Phase 2 · NCT03884465 Terminated
LIQ001 (0.45mg) Influenza Phase 1/2 · NCT01224262 Completed
Bupivacaine Hydrochloride Acute Pain Phase 1 · NCT02982889 Completed
Hyaluronic Acid Acute Pain Phase 1 · NCT02982889 Completed
LIQ861 Pulmonary Hypertension N/A · NCT06129240 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LQDA holds $396.1M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LQDA files for a raise →

👥 Who Owns LQDA

Insiders 19.4% Other 5%+ holders 9.6% Institutions (417 holders) 71% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 10,551,901 11.71% 2026-06-30
Dapice Joshua J. 5%+ holder (13G) 8,656,038 9.61% 2025-12-31
Farallon Capital Management, L.L.C. Institution (13G, 5%+) 8,365,038 9.28% 2026-06-30
David Edward Johnson
Director, 10% owner
Insider 8,163,229 9.06% 2026-06-16
Paul B Manning
Director
Insider 4,946,771 5.49% 2026-06-30
Roger Jeffs
Chief Executive Officer, Director · +128,996 options
Insider 2,167,515 2.41% 2026-10-09
Russell Schundler
General Counsel · +57,680 options
Insider 617,341 0.69% 2026-10-09
Michael Kaseta
CFO and COO · +63,448 options
Insider 340,148 0.38% 2026-10-09
Scott Moomaw
Chief Commercial Officer · +39,222 options
Insider 181,487 0.20% 2026-10-09
Jason Adair
Chief Business Officer · +38,722 options
Insider 177,269 0.20% 2026-10-26
Dana Boyle
Chief Accounting Officer · +28,609 options
Insider 164,028 0.18% 2026-10-26
Rajeev Saggar
Chief Medical Officer · +190,376 options
Insider 141,467 0.16% 2026-10-09

Share count 90,106,442 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-05-24 — NDA +9.4% +1.6% +9.9%

Browse all historical PDUFA outcomes →

Get the full LQDA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LQDA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.